Prosensa Awarded Best Biotech Pipeline 2013 at the Rare & Orphan Advocacy and Research (ROAR) Awards

Leiden, The Netherlands, Nov. 15, 2013 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA) the Dutch bio­phar­ma­ceu­ti­cal com­pa­ny focus­ing on rare dis­eases with a high unmet med­ical need, has been award­ed Best Biotech Pipeline 2013 in the Rare & Orphan Advocacy and Research (ROAR) Awards.
The ROAR Awards were announced dur­ing the 4th Annual World Orphan Drug Congress Europe, November 14-15, 2013, in Geneva, Switzerland. The inau­gur­al 2013 awards are an oppor­tu­ni­ty to rec­og­nize and hon­or achieve­ments by orga­ni­za­tions and indi­vid­u­als from indus­try, patient, and rare dis­ease advo­ca­cy com­mu­ni­ties.
“There is a des­per­ate unmet need in rare dis­eases, and we are ded­i­cat­ed to devel­op­ing treat­ments for patients who face very lim­it­ed options,” said Hans Schikan, CEO of Prosensa. “We are hon­ored to accept this award and would like to thank the judg­ing com­mit­tee for rec­og­niz­ing our efforts, and our many part­ners and advo­cates for their stead­fast sup­port.”
The Best Biotech Pipeline Award rec­og­nizes the breadth and depth of the company’s orphan drug pipeline, most notably its pio­neer­ing work in Duchenne mus­cu­lar dys­tro­phy, myoton­ic dys­tro­phy and Huntington’s dis­ease.

Leave a Reply

Your email address will not be published. Required fields are marked *